+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Urinary Tract Infection Treatment - Global Market Trajectory & Analytics

  • ID: 5140568
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
Global Urinary Tract Infection Treatment Market to Reach $11.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Urinary Tract Infection Treatment estimated at US$8.9 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027. Quinolones, one of the segments analyzed in the report, is projected to record a 3.4% CAGR and reach US$4.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Aminoglycosides segment is readjusted to a revised 3.7% CAGR for the next 7-year period.



The U.S. Market is Estimated at $2.6 Billion, While China is Forecast to Grow at 5.8% CAGR

The Urinary Tract Infection Treatment market in the U.S. is estimated at US$2.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

ß-lactam Segment to Record 3% CAGR

In the global ß-lactam segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$802.7 Million in the year 2020 will reach a projected size of US$978.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 3.2% CAGR through the analysis period.

Select Competitors (Total 41 Featured):
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Lipella Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • MerLion Pharmaceuticals GmbH
  • Mylan Pharmaceutical Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Urigen Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 2: World Historic Review for Urinary Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 3: World 15-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2018 & 2027
  • Table 4: World Current & Future Analysis for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 5: World Historic Review for Quinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 6: World 15-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
  • Table 7: World Current & Future Analysis for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 8: World Historic Review for Aminoglycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 9: World 15-Year Perspective for Aminoglycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
  • Table 10: World Current & Future Analysis for ß-lactam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 11: World Historic Review for ß-lactam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 12: World 15-Year Perspective for ß-lactam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
  • Table 13: World Current & Future Analysis for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 14: World Historic Review for Azoles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 15: World 15-Year Perspective for Azoles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
  • Table 16: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 17: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 18: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2018 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 19: USA Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 20: USA Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 21: USA 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • CANADA
  • Table 22: Canada Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 23: Canada Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 24: Canada 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • JAPAN
  • Table 25: Japan Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 26: Japan Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 27: Japan 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • CHINA
  • Table 28: China Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 29: China Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 30: China 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • EUROPE
  • Table 31: Europe Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Urinary Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 33: Europe 15-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2018 & 2027
  • Table 34: Europe Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 35: Europe Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 36: Europe 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • FRANCE
  • Table 37: France Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 38: France Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 39: France 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • GERMANY
  • Table 40: Germany Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 41: Germany Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 42: Germany 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • ITALY
  • Table 43: Italy Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 44: Italy Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 45: Italy 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • UNITED KINGDOM
  • Table 46: UK Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 47: UK Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 48: UK 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • SPAIN
  • Table 49: Spain Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 50: Spain Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 51: Spain 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • RUSSIA
  • Table 52: Russia Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 53: Russia Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 54: Russia 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • REST OF EUROPE
  • Table 55: Rest of Europe Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 56: Rest of Europe Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 57: Rest of Europe 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • ASIA-PACIFIC
  • Table 58: Asia-Pacific Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 59: Asia-Pacific Historic Review for Urinary Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 60: Asia-Pacific 15-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2018 & 2027
  • Table 61: Asia-Pacific Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 62: Asia-Pacific Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 63: Asia-Pacific 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • AUSTRALIA
  • Table 64: Australia Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 65: Australia Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 66: Australia 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • INDIA
  • Table 67: India Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 68: India Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 69: India 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • SOUTH KOREA
  • Table 70: South Korea Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 71: South Korea Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 72: South Korea 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • REST OF ASIA-PACIFIC
  • Table 73: Rest of Asia-Pacific Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 74: Rest of Asia-Pacific Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 75: Rest of Asia-Pacific 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • LATIN AMERICA
  • Table 76: Latin America Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 77: Latin America Historic Review for Urinary Tract Infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 78: Latin America 15-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2018 & 2027
  • Table 79: Latin America Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 80: Latin America Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 81: Latin America 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • ARGENTINA
  • Table 82: Argentina Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 83: Argentina Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 84: Argentina 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • BRAZIL
  • Table 85: Brazil Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 86: Brazil Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 87: Brazil 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • MEXICO
  • Table 88: Mexico Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 89: Mexico Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 90: Mexico 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • REST OF LATIN AMERICA
  • Table 91: Rest of Latin America Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 92: Rest of Latin America Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 93: Rest of Latin America 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • MIDDLE EAST
  • Table 94: Middle East Current & Future Analysis for Urinary Tract Infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 and % CAGR
  • Table 95: Middle East Historic Review for Urinary Tract Infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 96: Middle East 15-Year Perspective for Urinary Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2018 & 2027
  • Table 97: Middle East Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 98: Middle East Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 99: Middle East 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • IRAN
  • Table 100: Iran Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 101: Iran Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 102: Iran 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • ISRAEL
  • Table 103: Israel Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 104: Israel Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 105: Israel 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • SAUDI ARABIA
  • Table 106: Saudi Arabia Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 107: Saudi Arabia Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 108: Saudi Arabia 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • UNITED ARAB EMIRATES
  • Table 109: UAE Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 110: UAE Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 111: UAE 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • REST OF MIDDLE EAST
  • Table 112: Rest of Middle East Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 113: Rest of Middle East Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 114: Rest of Middle East 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
  • AFRICA
  • Table 115: Africa Current & Future Analysis for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 and % CAGR
  • Table 116: Africa Historic Review for Urinary Tract Infection Treatment by Segment - Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 and % CAGR
  • Table 117: Africa 15-Year Perspective for Urinary Tract Infection Treatment by Segment - Percentage Breakdown of Value Sales for Quinolones, Aminoglycosides, ß-lactam, Azoles and Other Segments for the Years 2012, 2018 & 2027
IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Johnson & Johnson
  • Lipella Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • MerLion Pharmaceuticals GmbH
  • Mylan Pharmaceutical Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Urigen Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll